Vestal Point Capital, LP

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$3.87B2026 Q3
Positions63
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.67.3%

Vestal Point Capital, LP reported 63 positions worth $3.87B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: ABVX (10.1%). Biggest move: add INSM ($282.5M).

10 / 63 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 ABVXAbivax S.A.$392.1M10.13%3,960,000———
▸ 2 NBIXNeurocrine Biosciences$354.6M9.16%2,500,000——+16.5%
▸ 3 BMRNBiomarin Pharmaceutical$331.5M8.56%5,525,000——-3.3%
▸ 4 ARWRArrowhead Pharmaceuticals$315.1M8.14%4,815,000——-32.5%
▸ 5 INSMInsmed$311.0M8.04%2,725,000——+7.7%
▸ 6 UTHRUnited Therapeutics$257.4M6.65%475,000——+8.5%
▸ 7 ASNDAscendis Pharma A/S$168.6M4.36%740,000——+20.9%
▸ 8 NRIXNurix Therapeutics$166.6M4.30%7,025,000——-37.9%
▸ 9 TARSTarsus Pharmaceuticals$159.9M4.13%2,033,625——+2.1%
▸ 10 ELVNEnliven Therapeutics$147.8M3.82%3,225,000——+3.9%

Pro Feature

The remaining 53 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Vestal Point Capital, LP hold as of Q3 2026?

Vestal Point Capital, LP reported 63 positions worth $3.87B in its Q3 2026 13F filing. Largest positions: ABVX (10.1%), NBIX (9.2%), BMRN (8.6%), ARWR (8.1%) and INSM (8.0%).

What did Vestal Point Capital, LP buy in Q3 2026?

New positions: TVTX, RCUS, BBIO, ZYME and COGT (15 in all). Added to: INSM, ARWR, ABVX, NBIX and ASND (23 in all).

What did Vestal Point Capital, LP sell in Q3 2026?

Reduced: ZBH, PODD, SNY, ELVN and BMRN (20 in all). Sold out entirely: ABT, AZN, RVMD, BCRX and RGEN (20 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.